Two Seniors Named Top 300 Regeneron Scholars

University School of Milwaukee seniors Anand George ’26 and Angela Wang ’26 were each named a top 300 scholar in the Regeneron Science Talent Search 2026, the nation’s oldest and most prestigious science and math competition for high school seniors. They were selected from over 2,600 entrants from 826 high schools across 46 states, Washington, D.C., Northern Mariana Islands, Puerto Rico, and 16 countries. 

George and Wang are two of only three students from Wisconsin to be chosen as a top 300 scholar. Each of the 300 scholars will be awarded $2,000, and their schools will be awarded $2,000 for each enrolled scholar.

Scholars were chosen based on their outstanding research, leadership skills, community involvement, commitment to academics, creativity in asking scientific questions and exceptional promise as STEM leaders demonstrated through the submission of their original, independent research projects, essays and recommendations.

Wang had been working on her project, titled "A Novel CNN-Based Approach for Early Alzheimer’s Prediction Using APOE Genetic Data," since July 2024. The results of her research demonstrate the feasibility of utilizing genetic data to advance Alzheimer's disease research. "It is truly an honor to be named a Regeneron STS scholar and join the community of people I was inspired by," she wrote. "With my research on Alzheimer's disease being recognized, I hope it helps make a change in the world, driving increased research and developing potential solutions that could improve the lives of millions globally."

George's project is titled "Prediction of Infection Risk in Multiple Myeloma Patients Treated With Bispecific Antibodies: Neural Network and Ensemble Approaches." He worked to develop machine learning models to predict the risk of infection amongst Multiple Myeloma patients who are being treated with bispecific antibodies (bsAbs). "To our knowledge, this is the first machine learning model that predicts infection risk within 90 days of initiating bsAbs for MM, and will be validated in larger patient cohorts," he wrote.